Aerpio Pharmaceuticals (ARPO) Stock Rating Lowered by HC Wainwright
Aerpio Pharmaceuticals (OTCMKTS:ARPO) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Tuesday, The Fly reports.
Other research analysts have also issued reports about the stock. Guggenheim lowered shares of Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. Cantor Fitzgerald set a $8.00 target price on shares of Aerpio Pharmaceuticals and gave the company a “buy” rating in a report on Monday, February 11th. Finally, National Securities downgraded shares of Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $8.25.
OTCMKTS:ARPO opened at $1.05 on Tuesday. Aerpio Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $5.00.
In related news, Director Muneer A. Satter acquired 63,818 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was bought at an average price of $2.35 per share, with a total value of $149,972.30. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Muneer A. Satter acquired 60,000 shares of the company’s stock in a transaction dated Wednesday, January 2nd. The shares were bought at an average cost of $1.80 per share, with a total value of $108,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 243,818 shares of company stock valued at $489,572. Corporate insiders own 38.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ARPO. Sphera Funds Management LTD. increased its stake in shares of Aerpio Pharmaceuticals by 2.6% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,131,819 shares of the company’s stock valued at $3,497,000 after acquiring an additional 28,265 shares during the last quarter. Vanguard Group Inc. acquired a new position in shares of Aerpio Pharmaceuticals during the 3rd quarter valued at about $3,331,000. Vanguard Group Inc acquired a new stake in Aerpio Pharmaceuticals during the 3rd quarter worth approximately $3,331,000. Acadian Asset Management LLC acquired a new stake in Aerpio Pharmaceuticals during the 4th quarter worth approximately $28,000. Finally, Bank of New York Mellon Corp acquired a new stake in Aerpio Pharmaceuticals during the 4th quarter worth approximately $36,000. 0.37% of the stock is owned by institutional investors.
Aerpio Pharmaceuticals Company Profile
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.
Read More: LIBOR
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.